Skip to main content
main-content

08-06-2021 | ASCO 2021 | Conference coverage | Video

Three-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer

Amit Bahl explains why 3-weekly cabazitaxel is still a valid option for treatment-naïve, HER2-negative, metastatic breast cancer even though the CONCEPT trial failed to show its superiority over weekly paclitaxel in this setting (7:14).

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits